Closed
Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service
NHS England
- Value
- £238,607.90
- Published
- 13 Oct 2026
- Deadline
- 10 Nov 2026
- Procedure
- Open procedure
- Category
- 85145000 — Services provided by medical laboratories
- Location
- UK
- Notice reference
- 096480-2026
Requirements summary
NHS England is procuring a national PSA laboratory processing and Virtual Screening Pathway Coordination service for the Targeted Prostate Cancer Screening Programme in England, focused on men at increased risk from an inherited BRCA2 variant. The service covers sample logistics, PSA processing, secure result transmission, failsafe management, programme reporting, and coordination of MRI and biopsy/urology appointments, with a value of GBP 238,607.90 over a 780-day contract period. Diagnostic MRI, biopsy, urology treatment, BRCA genetic testing and the national IT system are excluded.
Key requirements
- National PSA laboratory processing service for the Targeted Prostate Cancer Screening Programme in England
- Sample logistics from the agreed collection handoff point, receipt, accessioning and PSA result authorisation
- Secure result transmission, consumables provision, and sample and pathway tracking
- Failsafe management for invalid or failed samples and repeat collections
- Virtual Screening Pathway Coordination for MRI and biopsy/urology appointment scheduling
- Laboratory accreditation to UKAS/ISO 15189 with approved PSA assay and IQC/EQA quality controls
- Contract period of 780 days; tender deadline 10 November 2026; procured under the PSR 2023 regulations
Similar open notices
- Framework Agreement for DNA, Drug and Alcohol Testing ServicesCity & County of Swansea
- SPS-02361 Substance Screening & Related ServicesScottish Prison Service
- In-Vitro Diagnostics, Point of Care Testing & Pathology Services Project_1717SUPPLY CHAIN COORDINATION LIMITED
- In-Vitro Diagnostics, Point of Care Testing & Pathology ServicesSUPPLY CHAIN COORDINATION LIMITED
- NHS National Framework Agreement for Macitentan & Cladribine TabletsNHS England